Former Yaupon Therapeutics Raises $15 Million In Debt To Prepare To Commercialize Its First Product
This article was originally published in The Pink Sheet Daily
Executive Summary
Now called Ceptaris, the company is awaiting FDA approval of mechlorethamine gel, a topical formulation of a cytotoxin, for early-stage CTCL.